GlassScriptPhysician profile
Ronald M Andiman
NPI 1902936396
$51,121.36
in general payments reported to CMS, 2019-2025
58 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,731 · 2020: $15K · 2021: $16K · 2022: $13K · 2023: $3,066 · 2024: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15,339.11 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $10,430.68 | 2022 | |
| Abbvie INC. | $7,493.24 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceuticals, INC. | $6,168.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $930.64 | 2019-2024 | |
| Upsher-Smith Laboratories LLC | $812.16 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $780.87 | 2019-2023 | Rytary |
| Genzyme Corporation | $707.15 | 2019-2023 | |
| Lilly USA, LLC | $686.35 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Amgen INC. | $652.02 | 2019-2023 | Aimovig |
| Lundbeck LLC | $613.07 | 2020-2024 | Vyepti |
| Neurocrine Biosciences, INC. | $524.30 | 2020-2024 | Ingrezza, Ongentys |
| Pfizer INC. | $459.20 | 2023-2024 | |
| Sk Life Science, INC. | $449.56 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $442.00 | 2019-2024 | Ajovy, Austedo |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Andiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.